MedMira to Provide Multiplo Triple Tests as Screening Tool for Surveys
HALIFAX, April 22 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a global market leader in premium rapid diagnostic solutions, announced today that company president & CEO, Hermes Chan, delivered a presentation on MedMira's HIV, Hepatitis B and C rapid test, Multiplo(TM) HBV/HIV/HCV at the Behavioural Surveillance Surveys (BSS) Among Injecting Drug Users and Sex Workers workshop taking place in Bucharest, Romania. The workshop was organized by the United Nations Office on Drugs and Crime Romania (UNODC).
"We are pleased to have the opportunity to present our Multiplo test to the experts gathered for this important workshop. The awareness and interest in Multiplo continues to increase in Eastern Europe and participation in projects such as these surveillance surveys helps MedMira demonstrate the unequalled benefits of Multiplo to key healthcare decision makers in Romania and other countries in the region," said Hermes Chan, President & CEO, MedMira Inc. "MedMira is committed to supporting prevention and control programs such as this and we look forward to working together on future public health initiatives in other parts of the world where our Multiplo test can be of greatest value."
MedMira's Multiplo rapid tests will be used as the screening test for injecting drug users and sex workers, an important focus of the BSS starting at the end of May this year. Multiplo is the only commercially available rapid test in the world able to detect both HIV and Hepatitis C and B from a single specimen in less than three minutes. The quality and versatility of Multiplo make it ideal for use in programs like the BSS where patient testing will take place in a variety of settings, everywhere from healthcare facilities to mobile testing clinics.
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals around the world with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union.
In January 2006, MedMira launched the Maple Biosciences division to develop and commercialize diagnostic instruments based on two revolutionary biosensor-based technology platforms. The solutions developed by Maple Biosciences will enable routine laboratory tests to be performed in a matter of minutes, increasing laboratory automation, streamlining the diagnosis of multiple conditions and diseases and positioning MedMira to be a leading participant in the emerging fields of personalized medicine and molecular diagnostics. For more information visit www.maplebio.com.
MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in China. Maples Biosciences' labs are located in Toronto, Ontario. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
%SEDAR: 00013053E